TRML Projected Dividend Yield

Tourmaline Bio Inc ( NASDAQ : TRML )

Tourmaline Bio is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. In the organ transplant setting, which it calls Facilitated Allo-HSCT Therapy, could prevent organ rejection without the morbidity. Co.'s primary product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor.

20 YEAR PERFORMANCE RESULTS